Abbott Laboratories Agrees to $385 Million Settlement with DOJ Over Infant Formula Recall
Abbott Laboratories (ABT) has reached a settlement of $385 million with the U.S. Department of Justice over its 2022 recall of infant formula linked to contamination that resulted in two infant deaths. The company admitted fault for failing to maintain proper safety standards at its Michigan manufacturing plant, which led to the presence of deadly bacteria in some batches of baby formula. The settlement resolves federal claims related to these lapses and does not include an admission of criminal wrongdoing by Abbott. This resolution comes after a significant disruption in the U.S. infant formula supply chain last year due to the recall, highlighting regulatory scrutiny over food safety practices for vulnerable consumer products.
Tickers: $ABT
Topics: lawsuit product_recall regulation